**Supplementary Table 1.** Univariable unadjusted hazard ratios and 95% confidence intervals of covariates and all-cause mortality

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Hazard ratio (HR)** | **95% Confidence interval (CI) of HR** | ***p*-value** |
| *Histologic covariates* |  |
| Fibrosis stage0-1234 | Reference1.281.104.54 | Reference0.43-3.820.30-4.074.54-2.04 | 0.660.88<0.01 |
| Lobular inflammation0123 | Reference1.721.770.65 | Reference0.57-5.160.58-5.390.07-5.85 | 0.330.320.70 |
| Portal inflammation012 | Reference1.293.24 | Reference0.61-2.741.28-8.18 | 0.500.01 |
| Steatosis0123 | Reference0.610.400.56 | Reference0.14-2.730.09-1.780.12-2.54 | 0.520.230.45 |
| Ballooning012 | Reference2.814.16 | Reference1.29-6.131.39-12.41 | 0.010.01 |
| Acidophils01 | Reference1.39 | Reference0.43-4.56 | 0.58 |
| Mallory bodies012 | Reference1.441.64 | Reference0.65-3.190.22-12.14 | 0.360.62 |
| Microvesicular fat | 3.60 | 1.49-8.70 | <0.01 |
| NAFLD activity score | 1.07 | 0.87-1.32 | 0.51 |
| *Clinical covariates*  |  |
| Age | 1.06 | 1.03-1.08 | <0.01 |
| BMIUnderweight/NormalOverweightObese | Reference0.560.58 | Reference0.17-1.840.20-1.67 | 0.340.31 |
| GenderMaleFemale | Reference0.81 | Reference0.42-1.57 | 0.53 |
| RaceWhiteAsianBlack | Reference1.470.62 | Reference0.20-10.820.08-4.54 | 0.710.64 |
| EthnicityNon-HispanicHispanic | Reference1.16 | Reference0.54-2.48 | 0.70 |
| SmokerNever smokerFormer smokerCurrent smoker | Reference3.741.04 | Reference1.83-7.640.23-4.66 | <0.010.96 |
| Hypertension | 2.74 | 1.28-5.88 | 0.01 |
| Type 2 diabetes mellitus | 3.12 | 1.52-6.42 | <0.01 |
| Coronary artery disease | 1.84 | 0.71-4.74 | 0.21 |
| Chronic kidney disease | 0.98 | 0.23-4.08 | 0.97 |
| Congestive heart failure  | 0.91 | 0.12-6.66 | 0.92 |
| Obstructive sleep apnea | 0.35 | 0.08-1.47 | 0.15 |
| *Medications* |  |  |  |
| DPP-4 inhibitor | 2.04 | 0.28-14.88 | 0.48 |
| GLP-1 agonist | 0.97 | 0.13-7.05 | 0.97 |
| Metformin | 1.79 | 0.69-4.62 | 0.23 |
| Statin | 1.09 | 0.46-1.79 | 0.17 |